Barney S Graham

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1650-60. 2006
  2. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1638-49. 2006
  3. ncbi request reprint Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892 3017, USA
    Vaccine 25:4085-92. 2007
  4. pmc Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
  5. pmc Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein
    Teresa R Johnson
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Leukoc Biol 84:748-59. 2008
  6. pmc Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials
    Richard A Koup
    Immunology Laboratory, Immunology Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:6318-22. 2009
  7. pmc Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model
    Jie Liu
    Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
    J Virol 83:4934-41. 2009
  8. pmc A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 2610, Bethesda, MD 20892 3017, USA
    Vaccine 26:6338-43. 2008
  9. pmc Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals
    Janie Parrino
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 25:1513-25. 2007
  10. pmc Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization
    Cheng Cheng
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892 3005, USA
    J Virol 84:630-8. 2010

Detail Information

Publications93

  1. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1650-60. 2006
    ..Vaccine Research Center (VRC) 004 is the first phase 1 dose-escalation study of a multiclade HIV-1 DNA vaccine...
  2. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1638-49. 2006
    ..Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine...
  3. ncbi request reprint Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892 3017, USA
    Vaccine 25:4085-92. 2007
    ..Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation...
  4. pmc Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
    ..Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies...
  5. pmc Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein
    Teresa R Johnson
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Leukoc Biol 84:748-59. 2008
    ..These findings have important implications for the evaluation of candidate RSV vaccines...
  6. pmc Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials
    Richard A Koup
    Immunology Laboratory, Immunology Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:6318-22. 2009
    ..These data indicate that rAd5-based vaccines containing deletions in the E1, E3, and E4 regions do not induce appreciable expansion of vector-specific CD4(+) T cells...
  7. pmc Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model
    Jie Liu
    Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
    J Virol 83:4934-41. 2009
    ..Characterization of epitope-specific CD4 T cells by novel fluorochrome-conjugated peptide-I-A(b) tetramers allows detailed analysis of their roles in RSV pathogenesis and immunity...
  8. pmc A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 2610, Bethesda, MD 20892 3017, USA
    Vaccine 26:6338-43. 2008
    ..Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study...
  9. pmc Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals
    Janie Parrino
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 25:1513-25. 2007
    ..MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses...
  10. pmc Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization
    Cheng Cheng
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892 3005, USA
    J Virol 84:630-8. 2010
    ..These results have implications for future AIDS vaccine trials and the design of next-generation gene-based vaccine vectors...
  11. pmc Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope
    Tracy J Ruckwardt
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 185:4673-80. 2010
    ..These data demonstrate efficient viral clearance, and a protective effect of subdominant CD8(+) T cell responses...
  12. pmc Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:12236-44. 2010
    ..Collectively, these results provide a structural basis for RSV neutralization by antibodies that target a major antigenic site on the fusion glycoprotein...
  13. pmc Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses
    Nicolas Cuburu
    Laboratory of Cellular Oncology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 122:4606-20. 2012
    ..Thus, HPV vectors are attractive gene-delivery platforms for inducing durable intraepithelial cervicovaginal CD8+ T cell responses by promoting local proliferation and retention of primed antigen-specific CD8+ T cells...
  14. pmc Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
    Jorge A Tavel
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 44:601-5. 2007
    ..To evaluate the safety and immunogenicity of a candidate HIV DNA vaccine administered using a needle-free device...
  15. pmc Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 43:304-12. 2006
    ..Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide...
  16. pmc DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59340. 2013
    ..DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity...
  17. pmc Neonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice
    Tracy J Ruckwardt
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002377. 2011
    ..Thus, the functional properties of T cells are selectively modified by developmental factors in an epitope-specific and age-dependent manner...
  18. pmc Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection
    Jie Liu
    Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
    J Virol 84:10501-9. 2010
    ..Achieving the optimal balance of regulatory and effector T-cell function is an important consideration for designing future vaccines...
  19. ncbi request reprint Smallpox vaccines: Past, present, and future
    Janie Parrino
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Allergy Clin Immunol 118:1320-6. 2006
    ....
  20. pmc Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities
    Tracy J Ruckwardt
    Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:3019-28. 2009
    ....
  21. pmc Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV
    Teresa R Johnson
    Vaccine Research Center, NIAID, NIH, Bldg 40, Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 78:8753-60. 2004
    ....
  22. pmc Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
    Joseph P Casazza
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Infect Dis 207:1829-40. 2013
    ..The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can help control chronic viral infection. Unfortunately, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy...
  23. ncbi request reprint IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge
    Teresa R Johnson
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive MSC 3017, Building 40, Bethesda, MD 20892, USA
    J Immunol 170:2037-45. 2003
    ....
  24. pmc TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
    Teresa R Johnson
    Vaccine Research Center, Viral Pathogenesis Laboratory, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3017, USA
    Vaccine 27:3045-52. 2009
    ..Furthermore, these data underscore that amplification of anti-viral immune responses may result in immunopathology rather than immune-mediated protection...
  25. pmc A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:1396-404. 2011
    ..There are no licensed vaccines to prevent WNV in humans. The safety and immunogenicity of a first-generation WNV DNA vaccine was demonstrated in a clinical trial and a similar DNA vaccine has been licensed for use in horses...
  26. pmc Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV
    Teresa R Johnson
    VRC, NIAID, NIH, Bldg 40 Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 78:6024-32. 2004
    ....
  27. pmc Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infection
    John A Rutigliano
    Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 2502, 40 Convent Drive, MSC 3017, Bethesda, MD 20892 3017, USA
    Virology 362:314-9. 2007
    ..The hybrid mouse model provides a system to define rules of epitope hierarchy and better understand how antigen presentation and epitope competition affect the phenotype of effector and memory T cells...
  28. pmc Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 9:e91366. 2014
    ..m.) supported proceeding to a Phase 2 b efficacy study. Here we report comparison of the i.m., subcutaneous (s.c.) and intradermal (i.d.) routes of administration...
  29. doi request reprint Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 340:1113-7. 2013
    ..These studies should enable design of improved vaccine antigens and define new targets for passive prevention of RSV-induced disease...
  30. pmc DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults
    Surender Khurana
    Division of Viral Products, National Institute of Allergyand Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 208:413-7. 2013
    ..Enhanced HA1 binding and avidity after an interval of ≥12 weeks between prime and boost correlated with improved neutralization of homologous and heterologous H5N1 strains. Clinical trials registration NCT01086657. ..
  31. ncbi request reprint Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus
    John A Rutigliano
    Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 2502, 40 Convent Drive, MSC 3017, Bethesda, MD 20892 3017, USA
    Virology 337:335-43. 2005
    ..Furthermore, identification of this H-2b-restricted CTL epitope provides access to genetically modified H-2b mice for more detailed studies of CTL mechanisms in RSV infection...
  32. ncbi request reprint Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection
    Teresa R Johnson
    Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
    Pediatr Infect Dis J 23:S46-57. 2004
    ....
  33. pmc A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes, Bethesda, MD 20892 3017, USA
    Clin Vaccine Immunol 13:1267-77. 2006
    ....
  34. pmc Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4
    Lewis H McCurdy
    Vaccine Research Center NIAID NIH, 40 Convent Drive, MSC 3017, Building 40, Room 2502, Bethesda, MD 20892 3017, USA
    J Virol 78:12471-9. 2004
    ..These data support the continued development of MVA as an alternative candidate vaccine for smallpox...
  35. pmc A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial
    Julie E Martin
    Vaccine Research Center, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Infect Dis 196:1732-40. 2007
    ..West Nile virus (WNV) is a mosquito-borne flavivirus that can cause severe meningitis and encephalitis in infected individuals. We report the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study...
  36. pmc Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes
    Jason S McLellan
    Vaccine Research Center, NIAID NIH, 40 Convent Drive, Bldg 40, Rm 2613B, Bethesda, MD 20892, USA
    J Virol 85:7788-96. 2011
    ..The structural preservation of neutralizing epitopes in the postfusion state suggests that this conformation can elicit neutralizing antibodies and serve as a useful vaccine antigen...
  37. doi request reprint Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4(+) T cells
    Philippa Hillyer
    Laboratory of Immunobiochemistry, Division of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD, USA
    Eur J Immunol 43:3197-208. 2013
    ..While type I IFNs may beneficially enhance CD4(+) T-cell memory responses to vaccines or viral pathogens, they may also enhance the function of resident Th2 cells and exacerbate allergic inflammation. ..
  38. doi request reprint Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 342:592-8. 2013
    ..Immunization with site Ø-stabilized variants of RSV F in mice and macaques elicited levels of RSV-specific neutralizing activity many times the protective threshold. ..
  39. pmc Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
    Julie E Ledgerwood
    Vaccine Research Center, National Institute ofAllergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 208:418-22. 2013
    ..This study defines the shortest prime-boost interval associated with an improved response to MIV...
  40. pmc Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization
    Steevenson Nelson
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 4:e1000060. 2008
    ..Thus, in addition to a role in facilitating viral entry, changes in E protein arrangement associated with maturation modulate neutralization sensitivity and introduce an additional layer of complexity into humoral immunity against WNV...
  41. pmc RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology
    Tara L Gower
    Vaccine Research Center, Building 40, Room 2502, NIAID, NIH, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
    J Virol 79:5326-36. 2005
    ..These data suggest that viral filamentous protuberances characteristic of RSV infection are associated with RhoA signaling, are important for filamentous virion morphology, and may play a role in initiating cell-to-cell fusion...
  42. pmc Structural basis of respiratory syncytial virus neutralization by motavizumab
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Nat Struct Mol Biol 17:248-50. 2010
    ..Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure...
  43. ncbi request reprint Clonotype-specific avidity influences the dynamics and hierarchy of virus-specific regulatory and effector CD4(+) T-cell responses
    Jie Liu
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, MD, USA
    Eur J Immunol 44:1058-68. 2014
    ..These data indicate that MHC-peptide-TCR interactions can produce different kinetic and functional profiles in CD4(+) T-cell populations even when responding to the same epitope...
  44. pmc Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection
    John A Rutigliano
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:3014-23. 2004
    ..These results may prove useful in the development of new therapies to combat RSV infection or other inflammatory diseases...
  45. ncbi request reprint Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection
    John A Rutigliano
    Vaccine Research Center National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:3408-17. 2004
    ..In addition, the revelation that TNF-alpha is the principal mediator of RSV-induced illness means that administration of TNF receptor antagonists, in combination with antiviral therapy, may be an effective method to treat RSV infections...
  46. pmc Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e11995. 2010
    ..The peptide mixture was formulated as an emulsion in incomplete Freund's adjuvant (IFA)...
  47. pmc T Cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection
    Padma Billam
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
    J Biol Chem 286:4829-41. 2011
    ..Defining how epitope structure is interpreted to inform T cell function will improve the design of future gene-based vaccines...
  48. pmc Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus
    Teresa R Johnson
    Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Bethesda, Maryland, United States of America
    PLoS ONE 6:e16458. 2011
    ..Defining the influence of RSV on the function of selected DC subsets may improve the likelihood of achieving protective vaccine-induced immunity...
  49. pmc Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Mol Biol 409:853-66. 2011
    ....
  50. pmc Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses
    Melissa L Precopio
    Immunology Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 204:1405-16. 2007
    ..This quality of the CD8(+) T cell response may be at least partially responsible for the profound efficacy of these vaccines in protection against smallpox and serves as a benchmark against which other vaccines can be evaluated...
  51. doi request reprint Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease
    Peter L Collins
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6517, 50 South Dr MSC 8007, Bethesda, MD, 20892 8007, USA
    Curr Top Microbiol Immunol 372:3-38. 2013
    ..However, development of subunit or other protein-based vaccines for pediatric use is hampered by the possibility of enhanced disease and the difficulty of reliably demonstrating its absence in preclinical studies...
  52. ncbi request reprint Subunit recombinant vaccine protects against monkeypox
    Jean Michel Heraud
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 177:2552-64. 2006
    ..Their identification may guide future efforts to develop simpler, safer, and more effective vaccines for monkeypox and smallpox...
  53. doi request reprint Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine
    Robert A Seder
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Science 341:1359-65. 2013
    ..These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards...
  54. pmc Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2
    Teresa R Johnson
    Viral Pathogenesis Laboratorya and Structural Biology Section, b Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:1339-47. 2012
    ....
  55. ncbi request reprint Modified vaccinia Ankara: potential as an alternative smallpox vaccine
    Lewis H McCurdy
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
    Clin Infect Dis 38:1749-53. 2004
    ..Herein, we review alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses, and we suggest modified vaccinia Ankara (MVA) as a leading candidate for an alternative smallpox vaccine...
  56. pmc Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, FDA, Bethesda, MD 20892, USA
    J Virol 80:2092-9. 2006
    ..The new HIV-SELECTEST is a simple but robust diagnostic tool for easy implementation in HIV vaccine trials and blood banks worldwide...
  57. doi request reprint Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
    Nancy J Sullivan
    Biodefense Research Section, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 7:393-400. 2009
    ..This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule...
  58. doi request reprint The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors
    Richard A Koup
    Richard A Koup, Barney S Graham and Daniel C Douek are at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
    Nat Rev Immunol 11:65-70. 2011
    ..Our view is that investing in an iterative approach to human vaccine efficacy trials of sufficient size and sampling frequency will improve the likelihood that an immune correlate of vaccine protection will be defined...
  59. pmc New approaches to vaccine adjuvants: inhibiting the inhibitor
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 3:e57. 2006
  60. doi request reprint Challenges and opportunities for respiratory syncytial virus vaccines
    Barney S Graham
    Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
    Curr Top Microbiol Immunol 372:391-404. 2013
    ....
  61. ncbi request reprint DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Infect Dis 11:916-24. 2011
    ..We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improve antibody responses to inactivated influenza vaccination...
  62. ncbi request reprint Respiratory syncytial virus immunobiology and pathogenesis
    Barney S Graham
    Viral Pathogenesis Laboratory, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
    Virology 297:1-7. 2002
  63. pmc Pathogenesis of respiratory syncytial virus infection in the murine model
    R Stokes Peebles
    Vaccine Research Center, NIAID NIH, 40 Convent Drive, Building 40, Room 2502, Bethesda, MD 20892 3017, USA
    Proc Am Thorac Soc 2:110-5. 2005
    ..This article briefly reviews the clinical sequelae of RSV infection and then focuses on the mechanisms of viral pathogenesis...
  64. pmc Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01
    Yuxing Li
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:8954-67. 2011
    ..It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike...
  65. pmc Biological challenges and technological opportunities for respiratory syncytial virus vaccine development
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    Immunol Rev 239:149-66. 2011
    ..These new technologies may allow development of vaccines that can protect against RSV-mediated disease in infants and establish a new immunological paradigm in the host to achieve more durable protection against reinfection...
  66. pmc Viral and host factors in human respiratory syncytial virus pathogenesis
    Peter L Collins
    NIAID, NIH, 50 South Drive, MSC 8007, Bethesda, MD 20892, USA
    J Virol 82:2040-55. 2008
  67. pmc Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States
    Sylvain Cecchini
    Laboratory of Biochemical Genetics, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 16:597-604. 2009
    ..Using ELISA, we tested 404 human serum samples and established a range of antibody titers in a large U.S. adult population sample...
  68. pmc Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA
    Shari N Gordon
    Animal Models and Retroviral Vaccines Section, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 188:714-23. 2012
    ....
  69. ncbi request reprint Clinical trials of HIV vaccines
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Room 2502, MSC 3017, Bethesda, Maryland 20892 3017, USA
    Annu Rev Med 53:207-21. 2002
    ..Future advances will require the discovery of new immunogens that can induce neutralizing antibody, as well as efficacy trial evaluation of regimens optimized for CTL induction...
  70. pmc A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions
    Wei Shi
    Vaccine Research Center, NIAID, National Institutes of Health, Bldg 40, Rm 4502, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
    J Virol 82:6190-9. 2008
    ..The acidic character of this domain is likely responsible for its aberrant biochemical properties. These findings demonstrate that this region is essential for the assembly of the filamentous nucleocapsids that give rise to filoviruses...
  71. pmc Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation
    Lewis H McCurdy
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
    J Virol 77:1747-56. 2003
    ..Thus, manipulation of membrane lipid microdomains may lead to alterations in the production of viral filaments and RSV pathogenesis and provide a new pharmacologic target for RSV therapy...
  72. pmc IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse
    Weisong Zhou
    Department of Medicine, T 1218 MCN, Vanderbilt University Medical Center, Nashville, TN 37232 2650, USA
    Microbes Infect 8:2880-9. 2006
    ..These results suggest that IL-13 modulates illness from RSV-infection...
  73. ncbi request reprint Lessons from failure--preparing for future HIV-1 vaccine efficacy trials
    Barney S Graham
    J Infect Dis 191:647-9. 2005
  74. ncbi request reprint Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5
    Koichi Hashimoto
    Vanderbilt University, School of Medicine, Nashville, Tennessee 37232, USA
    Am J Respir Crit Care Med 170:306-12. 2004
    ..The impact of virus infection combined with allergic inflammation on mucus production may partially explain the more severe disease and airway hyperresponsiveness associated with RSV in the setting of atopy...
  75. ncbi request reprint Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Deborah Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 190:903-7. 2004
    ..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection...
  76. ncbi request reprint Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses
    Philip J Budge
    Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Antimicrob Chemother 54:299-302. 2004
    ....
  77. ncbi request reprint Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levels
    Koichi Hashimoto
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 2650, USA
    J Allergy Clin Immunol 116:550-7. 2005
    ....
  78. pmc RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G
    Philip J Budge
    Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    J Virol 78:5015-22. 2004
    ....
  79. ncbi request reprint Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans
    Michael A Eller
    Makerere University Walter Reed Project, Kampala, Uganda
    Vaccine 25:7737-42. 2007
    ....
  80. pmc Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness
    Koichi Hashimoto
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Virol 78:10303-9. 2004
    ..These results suggest that signaling through IP has antiviral effects while protecting against RSV-induced illness and that PGI(2) is a potential therapeutic target in the treatment of RSV...
  81. ncbi request reprint The role of IFN in respiratory syncytial virus pathogenesis
    Joan E Durbin
    Children s Research Institute, Children s Hospital, Columbus, OH 43205, USA
    J Immunol 168:2944-52. 2002
    ..These findings suggest that STAT1 activation by both type I (alphabeta) and type II (gamma) IFNs plays an important role in establishing a protective, Th1 Ag-specific immune response to RSV infection...
  82. ncbi request reprint Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent
    R Stokes Peebles
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    J Immunol 175:8253-9. 2005
    ..These results elucidate the pathways by which COX inhibition exerts a critical effect of the pulmonary allergen-induced inflammatory response and confirm that COX products are important regulators of allergic inflammation...
  83. ncbi request reprint Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice
    R Stokes Peebles
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Am J Respir Crit Care Med 165:1154-60. 2002
    ..We conclude that in the BALB/c mouse, COX inhibition with either a COX-1 or COX-2 inhibitor during allergen sensitization augments production of IL-13 and increases airway hyperresponsiveness...
  84. ncbi request reprint Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus
    Peter F Wright
    Departments of Pediatrics, Medical Center, Vanderbilt University School of Medicine, Nashville, TN 37232 2581, USA
    J Infect Dis 185:1011-8. 2002
    ..The response was not influenced by age, primary diagnosis, amount of virus recovered, or severity of illness but was suppressed by preexisting antibody...
  85. ncbi request reprint The complex relationship between respiratory syncytial virus and allergy in lung disease
    R Stokes Peebles
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Viral Immunol 16:25-34. 2003
    ..We also review the published murine models that combine RSV infection and allergic sensitization that attempt to explain the complex relationship between these two factors in regard to lung immunopathology and physiologic dysfunction...
  86. ncbi request reprint The histopathology of fatal untreated human respiratory syncytial virus infection
    Joyce E Johnson
    Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Mod Pathol 20:108-19. 2007
    ..These findings inform our understanding of RSV pathogenesis and may facilitate the development of new approaches for prevention and treatment...
  87. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
    ..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
  88. pmc NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus
    Teresa R Johnson
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Virol 76:4294-303. 2002
    ..These findings indicate that CD1d-dependent NK T cells play a role in expansion of CD8(+) T cells and amplification of antiviral responses to RSV...
  89. ncbi request reprint Cyclooxygenase inhibition augments allergic inflammation through CD4-dependent, STAT6-independent mechanisms
    Koichi Hashimoto
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    J Immunol 174:525-32. 2005
    ..These results illustrate the central role played by products derived from the COX pathway in the regulation of allergic immune responses...
  90. ncbi request reprint Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003
    Alexander C Schmidt
    Department of Pediatric Pulmonology and Immunology, Charite University Hospital, Berlin, Germany
    Virus Res 106:1-13. 2004
    ..Chanock Award for lifetime achievement in RSV research, an award named in honor of the person who started the field of RSV research by recovering the first human RS virus from infants with severe bronchiolitis in 1956...
  91. ncbi request reprint Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways
    Chun Geun Lee
    Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520 8057, USA
    J Biol Chem 277:35466-74. 2002
    ..These responses are mediated by multiple mechanisms with mucus metaplasia being dependent on and the inflammation and fibrosis being independent of an IL-13/IL-4R(alpha)/STAT-6 activation pathway...
  92. pmc Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis
    Yi Wei Tang
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Clin Microbiol 41:2633-40. 2003
    ..05). Immunohistochemistry for EBV or HHV-8 antigen showed viral antigen primarily in airway epithelial cells. These data support the concept that a herpesvirus could be a source of chronic antigenic stimulation in IPF...
  93. pmc Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers
    Philip J Budge
    Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Antimicrob Agents Chemother 47:3470-7. 2003
    ....